Azome Therapeutics was founded by University of Florida’s Chair of Pediatrics, Dr. Rashmin Savani and former Mallinckrodt Pharmaceuticals executives with a mission to revolutionize the treatment of inflammatory diseases. We are focused on severe acute inflammatory diseases and injuries that share a common biological mechanism: the NLRP3 Inflammasome. These inflammasome-mediated diseases include bronchopulmonary dysplasia (BPD), acute respiratory distress syndrome (ARDS), exacerbations in idiopathic lung fibrosis (ILF), acute lung injury, acute kidney injury, and sepsis. By specifically targeting the earliest activation signal for inflammasome activation, Azome’s technology represents a platform approach for addressing these severe unmet clinical needs.